Keith M. Kerr

Keith M. Kerr's AcademicInfluence.com Rankings

Keith M. Kerr

Philosophy

#6899

World Rank

#10017

Historical Rank

Logic

#3991

World Rank

#5230

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Keith M. Kerr's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Keith M. Kerr Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Keith M. Kerr's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. (2015) (2865)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (1839)
Tracking the Evolution of Non‐Small‐Cell Lung Cancer (2017) (1525)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (1102)
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution (2017) (1092)
PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project (2017) (1038)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (2017) (772)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (706)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (671)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018) (669)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (628)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (626)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (616)
PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project (2018) (525)
Guidelines on the radical management of patients with lung cancer (2010) (485)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies (2018) (376)
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. (2013) (368)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors (2021) (364)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (355)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (336)
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC (2019) (298)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. (2018) (294)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop (2010) (289)
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. (2017) (287)
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. (2022) (276)
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. (2005) (263)
UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening (2015) (250)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? (2015) (244)
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. (2012) (218)
Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens (2010) (218)
Pulmonary preinvasive neoplasia (2001) (215)
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations (2012) (211)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (209)
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study (2014) (208)
Inter-observer variation between pathologists in diffuse parenchymal lung disease (2004) (204)
Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study (2012) (196)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (191)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. (2018) (182)
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. (2019) (182)
Testing for ROS1 in non-small cell lung cancer: a review with recommendations (2016) (181)
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. (2016) (178)
The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. (2021) (177)
Thyroid transcription factor 1 in pulmonary adenocarcinoma (2004) (174)
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. (2014) (168)
Corrections to "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (166)
PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. (2019) (163)
Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. (2013) (150)
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group (2015) (149)
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. (2013) (146)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (145)
EGFR Mutation Testing Practices within the Asia Pacific Region (2015) (143)
Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category (2000) (142)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (141)
Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria (2006) (140)
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (138)
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma (2018) (137)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (133)
IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. (2020) (132)
Gene Expression Profiling in Non-Small Cell Lung Cancer (2004) (132)
Immune cell infiltrates and prognosis in primary carcinoma of the lung. (2000) (129)
Pulmonary adenocarcinomas: classification and reporting (2009) (127)
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2019) (119)
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? (2016) (116)
The association between atypical adenomatous hyperplasia and primary lung cancer (2000) (111)
The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening (2014) (111)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2019) (110)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (109)
Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. (2016) (105)
Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy (2005) (104)
The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, and Lung Adenocarcinoma (2011) (102)
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases (2017) (100)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee (2020) (97)
THE PATTERN OF K‐rasMUTATION IN PULMONARY ADENOCARCINOMA DEFINES A NEW PATHWAY OF TUMOUR DEVELOPMENT IN THE HUMAN LUNG (1997) (96)
Personalized medicine for lung cancer: new challenges for pathology (2012) (95)
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. (2018) (94)
Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. (1984) (94)
Merkel cell and squamous cell carcinomas arising in erythema ab igne (1993) (92)
Causes of pulmonary granulomas: a retrospective study of 500 cases from seven countries (2011) (92)
Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. (2016) (92)
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. (2016) (87)
The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. (2019) (87)
Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c‐erbB‐2 expression (1994) (85)
Quantitative Analysis of Tumor in Bronchial Biopsy Specimens (2010) (85)
PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation (2016) (82)
A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee. (2020) (78)
The Role of DNA Methylation in the Development and Progression of Lung Adenocarcinoma (2007) (75)
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). (2021) (74)
Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria (2014) (72)
Interobserver variation in the classification of thymic tumours – a multicentre study using the WHO classification system (2008) (71)
Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. (2015) (70)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (70)
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee (2020) (69)
Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee. (2020) (68)
Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. (2001) (64)
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. (2021) (64)
Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. (1996) (64)
Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. (1992) (63)
Partial regression in primary carcinoma of the lung: does it occur? (1998) (62)
Control of infectious synovitis. 12. Preparation of an agglutination test antigen. (1963) (61)
Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial (2013) (61)
The T cell differentiation landscape is shaped by tumour mutations in lung cancer (2020) (59)
A clonal expression biomarker associates with lung cancer mortality (2019) (59)
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center (2018) (58)
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? (2016) (58)
Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. (2016) (56)
Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. (2006) (55)
Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer (2014) (54)
BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas (2014) (50)
CONTROL OF INFECTIOUS SYNOVITIS 13. THE ANTIGEN STUDY OF (1964) (49)
Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial (2021) (49)
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report (2011) (47)
HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. (1997) (47)
Personalized cancer medicine and the future of pathology (2011) (45)
Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. (1992) (45)
The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer (NSCLC) recurrence and metastasis (2013) (45)
Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis (2021) (45)
Necrotizing sarcoid granulomatosis with extrapulmonary involvement. (1997) (45)
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. (2017) (42)
Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing (2014) (41)
Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer. (2000) (40)
Expression of CD44v6 but not E‐cadherin or β‐catenin influences prognosis in primary pulmonary adenocarcinoma (2000) (40)
Changing trends in incidence of lung cancer by histologic type in Scotland (2002) (39)
Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma (2004) (39)
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC (2011) (39)
Revolution in lung cancer: new challenges for the surgical pathologist. (2011) (38)
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer (2016) (37)
Hypersensitivity Pneumonitis A Perspective From Members of the Pulmonary Pathology Society. (2018) (36)
Killing of Aspergillus fumigatus spores by human lung macrophages: a paradoxical effect of heat-labile serum components. (1989) (36)
Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. (2002) (36)
An audit of the clinical investigation of pleural effusion. (1992) (36)
Lymphohistiocytoid Variant of Malignant Mesothelioma of the Pleura: A Series of 22 Cases (2007) (36)
Metastatic pulmonary ameloblastoma. An unusual case. (2003) (36)
Iron lung: bronchoscopic and pathological consequences of aspiration of ferrous sulphate. (1991) (35)
ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen (2016) (35)
PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer (2011) (35)
Cytology for PD-L1 testing: A systematic review. (2020) (34)
Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. (2012) (33)
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. (2019) (33)
Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. (2016) (33)
Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center. (2020) (32)
BTS guideline for the investigation and management of malignant pleural mesothelioma (2018) (32)
Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters (2014) (30)
PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples (2017) (30)
Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project (2012) (30)
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. (2013) (30)
Notification of tuberculosis: can the pathologist help? (1988) (30)
Is bronchoscopic lung biopsy helpful in the management of patients with diffuse lung disease? (2007) (28)
p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. (1997) (28)
Accelerated silicosis in Scottish stonemasons (1991) (28)
The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization (2014) (26)
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort (2019) (26)
Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung (2017) (26)
Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study (2014) (25)
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project (2018) (24)
Primary pulmonary osteosarcoma (2001) (23)
Pleomorphic, spindle cell, and giant cell carcinoma (2015) (23)
The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back? (2018) (23)
Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization. (2020) (22)
Pancoast syndrome: an unusual complication of pulmonary infection by Staphylococcus aureus. (1992) (21)
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing In Non-Small Cell Lung Cancer. (2020) (21)
Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification (2013) (21)
Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy (2012) (21)
Alveolar proteinosis with hypersensitivity pneumonitis: A new clinical phenotype (2010) (21)
Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project. (2021) (20)
Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (2017) (20)
Pachydermodactyly: confused with JCA. (1992) (19)
Using DNA sequencing data to quantify T cell fraction and therapy response (2021) (19)
Endobronchial lipoma associated with lobar bronchiectasis. (1991) (19)
Idiopathic pulmonary fibrosis: an update. (2006) (19)
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay (2020) (18)
In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. (2013) (17)
P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC (2018) (17)
In vitro thymidine labelling of human pulmonary neoplasms. (1983) (17)
Survival from malignant mesothelioma: where are we now? (2015) (17)
Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach (2020) (16)
An investigation into the role of human papillomavirus in endobronchial papillary squamous tumours. (1990) (15)
Tuberculosis of the trachea. (1987) (15)
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges. (2021) (15)
Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
Cell proliferation, cell loss and expression of bcl-2 and p53 in human pulmonary neoplasms. (1997) (14)
Cutaneous penile and perianal Crohn's disease treated with a combination of medical and surgical interventions (2008) (14)
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer (2022) (14)
EU–USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer (2006) (13)
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. (2020) (13)
EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). (2016) (13)
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe (2022) (13)
How to investigate a patient with suspected interstitial lung disease (2010) (12)
A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma. (1988) (12)
Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer. (2019) (12)
Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology (2020) (12)
Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC. (2017) (12)
A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens (2020) (12)
Inflammatory endobronchial polyposis with bronchiectasis in cystic fibrosis. (2001) (11)
A rare cause of recurrent massive pericardial and pleural effusions. (2008) (11)
The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer. (2013) (10)
Morphology and genetics of pre-invasive pulmonary disease (2004) (10)
Squamous cell carcinoma of an ileo‐anal pouch (2010) (10)
Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all? (2011) (10)
Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis. (2011) (10)
Molecular pathology of lung cancer (2012) (10)
Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (2011) (10)
Prognostic factors in resected lung carcinomas (2013) (10)
ALK testing in non-small cell lung carcinoma: what now? (2014) (10)
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? (2019) (10)
OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study (2018) (9)
RAPID SPECIFIC AGGLUTINATION OF EATON AGENT (MYCOPLASMA PNEUMONIAE) (1964) (9)
2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement. (2014) (9)
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine (2020) (9)
Classification of lung cancer: proposals for change? (2012) (8)
Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer (2019) (8)
Hydroxycarbamide‐induced pneumonitis (2009) (8)
Pulmonary veno-occlusive disease complicating Felty's syndrome. (1998) (8)
Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study (2014) (8)
The evolution of lung cancer and impact of subclonal selection in TRACERx (2023) (7)
Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer (2013) (7)
PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay. (2020) (7)
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future (2020) (7)
Transbronchial and Endobronchial Biopsies (2008) (7)
Spontaneous dissection of an anomalous systemic artery in the lung during pregnancy: a rare cause of hemoptysis. (2006) (7)
Influence of tumour patterns in mixed-type adenocarcinoma on post-operative survival: P1-166 (2007) (7)
Whole Transcriptome Analysis of Pre-invasive and Invasive Early Squamous Lung Carcinoma in Archival Laser Microdissected Samples (2017) (6)
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
Genomic–transcriptomic evolution in lung cancer and metastasis (2023) (6)
UK Lung Cancer RCT Pilot Screening Trial (2016) (6)
Pathology and personalized medicine in lung cancer (2013) (6)
The evolution of non-small cell lung cancer metastases in TRACERx (2023) (6)
Mycobacterium microti infection associated with spindle cell pseudotumour and hypercalcaemia: a possible link with an infected alpaca (2010) (6)
IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer. (2021) (6)
Precision Molecular Pathology of Lung Cancer (2017) (6)
Computer‐Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort (2018) (6)
Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management (2022) (6)
66 UK Lung Cancer Screening trial (UKLS): Prevalence data at baseline (2014) (6)
Calcified pulmonary chondromas in Carney's triad (2013) (6)
O-39 Cell cycle marker MCM2 in peripheral lung adenocarcinoma and its precursors (2003) (5)
Closed pleural biopsy to diagnose mesothelioma: dead or alive? (2009) (5)
Pathologist and molecular biologist, ever the twain shall meet? (2009) (5)
MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists (2018) (5)
A comparison of cobalt (57Co) bleomycin scanning and contrast-enhanced CT scanning for assessment of the mediastinum in lung cancer. (1990) (5)
Sarcoidosis (2009) (5)
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee. (2022) (5)
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists (2021) (5)
UNITED KINGDOM LUNG CANCER SCREENING (UKLS) TRIAL (2011) (5)
The differential diagnosis of pulmonary pre-invasive lesions (2007) (4)
9002 ORAL Round Robin Test to Evaluate the Reproducibility of a Therapeutically Relevant Immunohistochemical Score for the Categorization of Non-Small Cell Lung Cancer (NSCLC) Into Tumours With High and Low Epidermal Growth Factor Receptor (EGFR) Expression (2011) (4)
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA (2023) (4)
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. (2021) (4)
The Classification of Pre-invasive Lesions (2012) (4)
Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2023) (4)
Mixed Squamous Cell and Glandular Papilloma (2017) (4)
Pathological and clinical investigation of pulmonary atypical adenomatous hyperplasia and its association with primary lung adenocarcinoma (2000) (3)
Histological appearances of putative montelukast related Churg–Strauss syndrome (2008) (3)
D4-05: Is survival after surgical resection of lung cancer influenced by the presence of atypical adenomatous hyperplasia (AAH)? (2007) (3)
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC (3)
Relapsing necrotising sarcoid granulomatosis in a young patient (2007) (3)
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (3)
Lung adenocarcinoma promotion by air pollutants (2023) (3)
39: Mutation analysis and association with TTF1 expression in lung non-squamous NSCLC (2015) (3)
Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment (2022) (3)
Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: A prospective study. (2012) (3)
Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study (2019) (3)
Abstract 3631: United Kingdom lung cancer screening trial (UKLS): First 88897 approaches. (2013) (2)
The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. (2013) (2)
Current issues in pulmonary adenocarcinoma (2008) (2)
Penile metastases from carcinoma of the prostate. (1997) (2)
Thymidylate synthetase (TS) immunohistochemistry (IHC): Feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC. (2010) (2)
81 The uniqueness of the United Kingdom Lung Cancer Screening trial (UKLS) – a population screening study (2013) (2)
Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial (2022) (2)
Endobronchial ultrasound transbronchial needle aspiration at Aberdeen Royal Infirmary: the initial experience. (2012) (2)
non-invasive mediastinal staging . lymph nodes in lung cancer : implications for Pathological assessment of mediastinal (2)
The 2015 World Health Organisation Classification of Lung Cancer (2018) (2)
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee (2022) (2)
P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer (2019) (2)
Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project (2015) (2)
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (2)
External Quality Assessment for ALK Immunohistochemistry Testing in Lung Adenocarcinoma Within the European Thoracic Oncology Platform Lungscape Project (2012) (2)
Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up† (2015) (2)
Repair of iatrogenic distal tracheal rupture by left thoracotomy. (2007) (2)
OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER: A SIMULATION EXPERT MULTIDISCIPLINARY TUMOR BOARD (2013) (2)
Pilot Screening Trial : baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening ' (2016) (1)
Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy (2018) (1)
30 – Precursors of Malignancy (2017) (1)
Pulmonary Pathology (2018) (1)
Spencer's Pathology of the Lung: Pulmonary pre-invasive disease (2013) (1)
Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. (2017) (1)
Clinical recommendations for EGFR mutation testing in non-small cell lung cancer (NSCLC): Results from a European workshop. (2010) (1)
Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth - A proposal by the IASLC Pathology Committee. (2022) (1)
O-41 Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in lung adenocarcinoma and its precursors (2003) (1)
PP 56 Suitability of advanced non-small cell lung cancer biopsies for prospective, multiple molecular analyses in clinical trials (2011) (1)
Responses of specific-pathogen-free chicks to concomitant infections of reovirus (WVU-2937) and infectious bursal disease virus. (1983) (1)
A molecular profile that predicts response to platinum based chemotherapy in non-small cell lung cancer (NSCLC) patients (2004) (1)
1382TiPInvestigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study (2017) (1)
Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx (2023) (1)
3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project (2015) (1)
Precision Medicine in Lung Cancer (2018) (1)
A rare cause of pleural disease. (2013) (1)
Preneoplastic and Preinvasive Lesions (2008) (1)
Molecular Testing in Lung Cancer Pathology (2014) (1)
Histological diagnosis: recent developments (2015) (1)
P3.01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules: Topic: Morphology (2017) (1)
Results of a Pilot External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non-Small Cell Lung Cancer Managed by EMQN, ESMO, ESP, and ETOP (2011) (1)
Bringing onco-innovation to Europe’s healthcare systems: the unexploited potential of biomarker testing, real world evidence and the potential of Tumour Agnostics. The lesson from BRCA1/2 genetic testing (2020) (0)
Revised Classification for Adenocarcinoma (2012) (0)
Update on large cell carcinomas of the lung (2014) (0)
Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC). (2018) (0)
Vindesine and etoposide chemotherapy in the management of patients with small cell lung cancer and poor prognosis. (1991) (0)
Atypical Adenomatous Hyperplasia, Lung (2018) (0)
Best practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions (2021) (0)
UK Lung Cancer Screening trial documentation (2016) (0)
33IN THE CONCEPT OF NEUROENDOCRINE TUMORS (2011) (0)
75: EGFR-mutant non-small cell lung cancer in Aberdeen, Scotland – Treatment and outcomes (2017) (0)
Influence of CD44v6, E-cadherin and β-catenin expression on the behaviour of primary lung adenocarcinoma (2000) (0)
United Kingom lung cancer screening (UKLS) trial [Conference abstract] (2011) (0)
Characterization of Salmonella hadar (2013) (0)
An unusual case of ALK mutation in large-cell neuroendocrine carcinoma of lung and response to alectinib (2021) (0)
P-654 Large cell neuroendocrine lung carcinoma: Clinically more small than non-small? (2003) (0)
MA 06.06 Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort (2017) (0)
Liquid Biopsy in Lung Cancer. (2016) (0)
Computed tomography scan findings and the early outcome of patients referred to the multidisciplinary team (2016) (0)
Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer. (2010) (0)
P1.02-025 Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (0)
44 The first 100 endobronchial ultrasound transbronchial needle aspirations at Aberdeen Royal Infirmary (2012) (0)
Mucoepidermoid Carcinoma, Lung (2017) (0)
Wang ZZ . ' I ' racheobronchial tumors : an eighteen year series from Capital Hospital , Peking , China (0)
O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer (2019) (0)
1199PDPREVALENCE AND CLINICAL OUTCOMES FOR PATIENTS WITH MET PROTEIN EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN EUROPE: RESULTS FROM THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT. (2014) (0)
Molecular mechanisms of cytotoxicity and pathogenesis in non-small cell lung cancer (NSCLC) using gene expression profiling. (2003) (0)
18 NSCLC second line therapy with erlotinib: review of patients' outcomes (2011) (0)
Authors' response. (2013) (0)
Necrosis as a predictor of infection in granulomatous lung disease (2013) (0)
Quality improvement in lung cancer: Aims and achievements in the North of Scotland (2010) (0)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (0)
Agreement Of Pathological Diagnosis In Fibrosing Interstitial Pneumonia (2010) (0)
7IN WHAT CAN BE ACHIEVED WITH PRESENT PATHOLOGY (2011) (0)
Minute Meningothelial Nodules (2017) (0)
Authors' response (2012) (0)
Minimally Invasive Adenocarcinoma (MIA) (2017) (0)
Lung Cancer RCT Pilot Screening Trial : baseline fi ndings from the screening arm provide evidence for the potential implementation of lung cancer screening (2016) (0)
Adenocarcinoma In Situ (2018) (0)
DNA Methylation Changes in Developing Lung Adenocarcinoma: P2-017 (2007) (0)
5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING (2011) (0)
Biomarkers for the classification of highly malignant neuroendocrine lung carcinoma (2012) (0)
Improving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions. (2023) (0)
PP 15 BRCA1 expression is required for efficacy of vinorelbine and is a predictive biomarker in malignant mesothelioma (2011) (0)
HBME-1andantithrombomodulin inthe differential diagnosis ofmalignant mesothelioma ofpleura (1997) (0)
Mucous Gland Adenoma, Lung (2017) (0)
OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer (2019) (0)
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
7 Acquired resistance to TKIs in NSCLC; detection of low level T790M using an LNA clamp sequencing method (2014) (0)
Lecce (12) found infectious-synovitis-derived pleuro- pneumonia-like organisms (ISD-PPLO) colonies growing as (2016) (0)
The Lungscape Project. (2012) (0)
P-679 EU-US pathologypanel for uniform diagnosis in randomised controlled trials for ct screening of lung cancer. Learning phase in diagnosis of early lung cancer (2005) (0)
25 Interobserver agreement in the evaluation of urine cytology for the detection of urothelial malignancy (2006) (0)
P2.13-25 Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland (2018) (0)
Details of the Liverpool Lung Project risk model (version 2) (2016) (0)
311 MAGEA tumour antigens mediate platinum cytotoxicity in NSCLC (2010) (0)
Erlotinib use in NSCLC: how are we getting on? (2008) (0)
Pronostic et cible de la therapie de cancer (2006) (0)
Neoantigen-directed immune escape in lung cancer evolution (2019) (0)
PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases (2017) (0)
57 Squamous cell and adenocarcinoma ‘lineage’ markers in large cell carcinoma of the lung (2012) (0)
222 MesobanK – a UK based bioresource for malignant mesothelioma (2014) (0)
Bronchioloalveolar Carcinoma/adenocarcinoma-in-situ (2012) (0)
Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort (2019) (0)
21 High sensitivity detection of epidermal growth factor receptor (EGFR) T790M mutants in non-small-cell lung cancer (2013) (0)
Docetaxel first line use in advanced NSCLC (2008) (0)
Clear Cell Tumor of Lung, Cytological Findings (2017) (0)
Molecular Pathology of Precursor and Pre-invasive Lesions (2012) (0)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (0)
Response. (2020) (0)
Advances in Surgical Pathology: Lung Cancer (2012) (0)
P2-289: Docetaxel with platinum as first line chemotherapy in advanced non-small cell lung cancer (NSCLC) (2007) (0)
Abstract IA15: Bringing personalized therapy into the clinic: Can pathology deliver? (2012) (0)
Radiological interventions and outcomes (2016) (0)
12 Current and ex-smokers with primary lung adenocarcinoma should be tested for EGFR mutation (2013) (0)
Data tables showing demographics of response and recruitment (2016) (0)
Authors' response (2011) (0)
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. (2023) (0)
Trial randomisation method (outlined in Chapter 2) (2016) (0)
A Prospective Multicenter Study for ALK IHC plus Metastasized NSCLC (2015) (0)
Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
139TiPA non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS) (2017) (0)
Significant decline in cancer diagnostic testing in U.S. CMS population during the COVID-19 pandemic. (2021) (0)
Optimizing measurement of EGFR mutation status in NSCLC. (2010) (0)
1630PDAssociation of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort (2017) (0)
P-104 Identification of the lysosomal programmed cell death (PCD)pathway as a critical determinant of clinical response in Non-Small Cell Lung Cancer (NSCLC) (2005) (0)
Proposed revisions to the classification of Adenocarcinoma (2012) (0)
Endobronchial ultrasound transbronchial needle aspiration at Aberdeen Royal Infirmary: How are we doing? (2012) (0)
Tuberculosis through the rose tinted spectacles of the EBUS endoscopist: be aware of the bias response (2012) (0)
P3.04-009: Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project (2015) (0)
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
The pathology of screen-detected lesions (2006) (0)
Recruitment of participants (2016) (0)
An analysis of mRNA and long non-coding RNA (lncRNA) expression during the progression from pre-invasive lesions (PL) to invasive squamous cell carcinoma (SqCC) of the bronchus (2013) (0)
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (0)
Hypoxia PET/CT and Colorectal Cancer: A Case Report (2020) (0)
Summary report of UK Lung Cancer Screening sample quality control (2016) (0)
11 Second-line erlotinib in unselected NSCLC: audit of benefit (2011) (0)
Results of the Second Pilot External Quality Assurance Scheme for Somatic Egfr Mutation Testing in Non-Small-Cell Lung Cancer (NSCLC) (2012) (0)
ETOP activity in the field of biomarkers and predictors (2012) (0)
Body composition and lung cancer-associated cachexia in TRACERx (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Keith M. Kerr?

Keith M. Kerr is affiliated with the following schools:

University of Tsukuba
West Virginia University
University of Aberdeen